This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Anthim industry.
What is the expected value of the anthim market over the forecast period?
The anthim market size has grown strongly in recent years. It will grow from $3,994.45 million in 2024 to $4,300.44 million in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to government initiatives for emergency stockpiling, advancements in monoclonal antibody production technologies, heightened global awareness of biological threats, and the rising need for innovative therapeutic approaches in infectious disease management.
The anthim market size is expected to see strong growth in the next few years. It will grow to $5,715.28 million in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to enhancing monoclonal antibody production, expanding healthcare infrastructure in emerging markets, and increasing global awareness of biological threat mitigation strategies. Major trends in the forecast period include advanced biopharmaceutical research, expanding public-private partnerships in biodefense initiatives, rising regional diversification in pharmaceutical production, and an emphasis on streamlined regulatory pathways to accelerate drug approval processes.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19875&type=smp
What industry dynamics are acting as key growth drivers for the anthim market?
The rising prevalence of bacterial infections is expected to propel the growth of the anthim market going forward. Bacterial infections refer to diseases caused by harmful bacteria that invade the body, multiply, and produce toxins. The rise in bacterial infections stems from antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Anthim (obiltoxaximab) is used to treat anthrax, a bacterial infection caused by Bacillus anthracis, by neutralizing the anthrax toxin and preventing it from entering cells, thereby mitigating its harmful effects. For instance, in December 2023, according to report published by World Health Organization (WHO) a Switzerland based health authority, suspected anthrax cases in Zambia rose from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% CFR), across 44 districts in nine of the country’s ten provinces. Therefore, the rising prevalence of bacterial infections is driving the growth of the anthim market.
What are the fastest-growing segments in the anthim market forecast period?
The anthim market covered in this report is segmented –
1) By Type: Adult; Children
2) By Clinical Indications: Inhalational Anthrax Treatment; Post-Exposure Prophylaxis (PEP) For Inhalational Anthrax; Use In Pediatric And Adult Populations
3) By Application: Hospital; Drugs Store; Other Applications
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/anthim-global-market-report
What are the most notable trends influencing investment in the anthim sector?
The key trend in the anthem market is adopting a strategic international contract approach such as public-private partnerships (PPPs) to enhance technology integration and expand market reach. Public-private partnerships (PPPs) refer to collaborations between government agencies and private pharmaceutical companies to jointly fund, research, and distribute medical treatments or drugs, often to address public health needs or stimulate innovation. For instance, in April 2022, Heat Biologics, Inc., a US-based biotechnology company, through its Elusys Therapeutics subsidiary, a US-based pharmaceutical company, secured a $5.65 million (CAD $7.9 million) contract with the Canadian government to supply ANTHIM, a treatment for inhalation anthrax, for its National Emergency Strategic Stockpile. This marks ANTHIM’s first international procurement aimed at addressing anthrax biothreats amidst global geopolitical concerns. This contract is specifically for the supply of ANTHIM (obiltoxaximab), a monoclonal antibody treatment used for inhalational anthrax, which is a serious infectious disease caused by Bacillus anthracis spores.
Which major players hold significant market share in the anthim sector?
Major companies operating in the anthim market include Elusys Therapeutics Inc, Hikma Pharmaceuticals
Which regional segments are forecasted to witness the fastest growth in the anthim market?
North America was the largest region in the anthim market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Anthim Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19875
Need Customized Data On Anthim Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19875&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
